Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2023-09-20 Director's Dealing
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2023-09-20 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 19, 2023, by Stoke Therapeutics, Inc. The key content is the announcement of the election of a new director, Ian F. Smith, to the Board of Directors, including details about his term, compensation, and stock option grant. There is no financial data or report content; rather, it is an announcement of a change in the company's board. This matches the description of Board/Management Information filings (MANG). The document length is 5434 characters, sufficient to contain detailed information about the director appointment. Therefore, the correct classification is MANG.
2023-09-20 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is a preliminary proxy statement for a Special Meeting of Stockholders of Stoke Therapeutics, Inc. The content includes details about the meeting, voting instructions, proposals to be voted on, and other proxy-related information. There is no indication that this is a full annual report, earnings release, or other financial report. The document is not an announcement of a report but the proxy statement itself. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2023-09-18 English
FORM 4 SUBMISSION
Director's Dealing
2023-09-08 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2023, reporting the issuance of a press release announcing financial results for the quarter ended June 30, 2023. The text states that the press release is attached as an exhibit, indicating this filing is a current report notifying the market of the earnings release rather than the earnings release itself. The document length is 3049 characters, which is relatively short and consistent with a Form 8-K announcement. Therefore, this is an Earnings Release announcement filing (ER).
2023-08-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.